Graham McIlroy Loretta Ford Jawad M Khan
10.1186/s40360-016-0045-1
BMC Pharmacol Toxicol
2016 Jan 16;17:2.
CC BY
https://pubmed.ncbi.nlm.nih.gov/26772803/
Adamantane / toxicity Cannabinoids / toxicity Designer Drugs / toxicity Inhalant Abuse / physiopathology Myocardial Infarction / etiology Psychotropic Drugs / toxicity
Adamantane / toxicity Cannabinoids / toxicity Designer Drugs / toxicity Inhalant Abuse / physiopathology Myocardial Infarction / etiology Psychotropic Drugs / toxicity Case Reports Adamantane / administration & dosage Adamantane / urine Administration, Inhalation Adult Cannabinoids / administration & dosage Cannabinoids / urine Designer Drugs / administration & dosage Designer Drugs / analysis Diagnosis, Differential Emergency Medical Services England Humans Inhalant Abuse / diagnosis Inhalant Abuse / urine Male Myocardial Infarction / therapy Psychotropic Drugs / administration & dosage Psychotropic Drugs / urine Toxicokinetics Treatment Outcome Cannabinoids Designer Drugs Psychotropic Drugs Adamantane
PMC4715335
26772803
Acute myocardial infarction, associated with the use of a synthetic adamantyl-cannabinoid: a case report
2016